A Phase 3 interventional study of D961H capsule 10mg and D961H sachet 10mg in Reflux Esophagitis, Gastric Ulcer and Duodenal Ulcer, sponsored by AstraZeneca. Completed at 15 sites in Japan. Open to participants aged 1 Year to 14 Years. Per ClinicalTrials.gov, last updated 2026-03-04.
Sponsored by AstraZeneca · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Esophagitis, Peptic by AstraZeneca — none open to participants now, none under way, none of them phase 3. Esophagitis, Peptic · AstraZeneca.
Among the 12 studies in Esophagitis, Peptic by AstraZeneca, this one is the only one that started in 2018, is one of 5 in phase 3, and was the 12th registered.
83 studies on the registry are indexed under Esophagitis, Peptic; 16 are open to participants now.
Browse Esophagitis, Peptic studies →None of the 12 studies in Esophagitis, Peptic by AstraZeneca is open now. The open studies under Esophagitis, Peptic, anywhere →
Of the 8 Esophagitis, Peptic studies recruiting now, 3 set no upper age limit and 3 stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.
This study: 1 Year to 14 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 50 is below the median of 135 across 60 interventional studies indexed under Esophagitis, Peptic.
Median enrollment 114 across the 8 interventional studies, 2,643 across the 4 observational. Of the 12 that completed or were terminated, 6 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Esophagitis, Peptic by AstraZeneca, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an open label, parallel group, multi-centre, phase III study to assess the safety and efficacy of D961H in maintenance therapy following initial healing therapy in Japanese paediatric patients with reflux esophagitis, and to assess the safety and efficacy of D961H in Japanese paediatric patients treated with long term non-steroidal anti-inflammatory drugs or low-dose aspirin therapy who have a documented medical history of gastric ulcer or duodenal ulcer diagnosis.
Doses of D961H in this study is set for the 2 groups (weight more than equal 10 kg to less than 20 kg and weight more than equal 20 kg) in the maintenance therapy for healed reflux esophagitis group and the prevention of gastric ulcer or duodenal ulcer recurrence by non-steroidal anti-inflammatory drugs or low-dose aspirin therapy group, Primary endpoints are evaluated at week 32. Further, this study is designed to evaluate the long term efficacy and safety of D961H for a maximum of 52 weeks, in consideration of the medical needs for long term proton pump inhibitor treatment. Patient can continue study treatment up to 52 weeks, if they want
Subjects are allocated to four groups based on their disease and weight.
Number of Subjects
Maintenance therapy for healed reflux esophagitis study part:
Prevention of gastric ulcer or duodenal ulcer recurrence associated with long term non-steroidal anti-inflammatory drugs or low-dose aspirin therapy study part:
All subjects have a D961H administration for 32 or 52 weeks. all esophagogastroduodenoscopy findings are reviewed by central evaluation committee and study is conducted based on the judgement of central evaluation committee.
Data are entered in electric data capture system at study site by site staffs and all data are verified with source data by site monitors during the study.
Analyses will be performed by AstraZeneca or its representatives. A comprehensive statistical analysis plan will be developed and finalised before database lock and will describe the subject populations to be included in the analyses, and procedures for accounting for missing, unused, and spurious data. This section is a summary of the planned statistical analyses of the primary and secondary endpoints. Any deviations from this plan will be reported in the clinical study report.
Efficacy analyses are intended for Efficacy Analysis Set. ・Efficacy Analysis Set:All subjects who take at least 1 dose of the investigational product and have at least 1 efficacy datum assessment during the maintenance/prevention therapy period, and who have no important protocol deviation.
All safety analyses are performed on the Safety Analysis Set.
・Safety Analysis Set:All subjects who take at least 1 dose of the investigational product and have any post-treatment assessment.
Frequency and incidence rate of adverse events (AEs), serious adverse events (SAEs), discontinuation of investigational product due to adverse events (DAEs) and other significant adverse events (OAEs) will be presented by MedDRA System Organ Class (SOC) and Preferred Term (PT) for each group. In addition, summaries of AEs will be further broken down by maximum intensity and relationship to the investigational product as assigned by investigators
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For healed reflux esophagitis study
For prevention of gastric ulcer or duodenal ulcer recurrence study
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Initial healing phase (8 weeks), D961H 10 mg once-daily; Maintenance phase (24 or 44 weeks), D961H 10 mg once-daily
Drug: D961H capsule 10mg · Drug: D961H sachet 10mg
Initial healing phase (8 weeks), D961H 20 mg once-daily; Maintenance phase (24 or 44 weeks) starts with D961H 10 mg once-daily and may be increased to 20 mg once-daily based on investigator's discretion
Drug: D961H capsule 10mg · Drug: D961H sachet 10mg
D961H 10 mg once-daily (32 or 52 weeks)
Drug: D961H capsule 10mg · Drug: D961H sachet 10mg
D961H starts with 10 mg once-daily, and may be increased to 20 mg once-daily based on investigator's discretion (32 or 52 weeks)
Drug: D961H capsule 10mg · Drug: D961H sachet 10mg
All Groups can select either capsule or sachet during the study.
Also known as: esomeprazole
All Groups can select either capsule or sachet during the study.
Also known as: esomeprazole
Presence/Absence of Reflux Esophagitis Relapse
Maintenance therapy for healed reflux esophagitis study part: Presence/absence of reflux esophagitis relapse from 8 to 32 weeks for all participants by assessment of the composite endpoint (reflux esophagitis -related symptoms or optional esophagogastroduodenoscopy findings) during the maintenance therapy.
Time frame: 8 to 32 weeks
Presence/Absence of Gastric Ulcer or Duodenal Ulcer Recurrence
Prevention of gastric ulcer or duodenal ulcer recurrence associated with long term non-steroidal anti-inflammatory drugs or low-dose aspirin therapy study part: Presence/absence of gastric ulcer or duodenal ulcer recurrence from 0 to 32 weeks for all participants by assessment of the composite endpoint (gastric ulcer or duodenal ulcer-related symptoms or optional esophagogastroduodenoscopy findings) during the prevention therapy.
Time frame: 0 to 32 weeks
Adverse Events During Reflux Esophagitis Maintenance Therapy
Maintenance therapy for healed reflux esophagitis study part: Safety from 8 to 32 weeks for all participants. Number of participants with any adverse event during the period.
Time frame: 8 to 32 weeks
Adverse Events During Gastric Ulcer or Duodenal Ulcer Recurrence Prevention Therapy
Prevention of gastric ulcer or duodenal ulcer recurrence associated with long term non-steroidal anti-inflammatory drugs or low-dose aspirin therapy study part: Safety from 0 to 32 weeks for all participants. Number of participants with any adverse event during the period.
Time frame: 0 to 32 weeks
Presence/Absence of Reflux Esophagitis Relapse
Presence/absence of reflux esophagitis relapse from 8 to 52 weeks for participants who continued the study treatment after Week 32 by assessment of the composite endpoint (reflux esophagitis-related symptoms or optional esophagogastroduodenoscopy findings) during the maintenance therapy.
Time frame: 8 to 52 weeks
Presence/Absence of Gastric Ulcer or Duodenal Ulcer Recurrence
Presence/absence of gastric ulcer or duodenal ulcer recurrence from 0 to 52 weeks for participants who continued the study treatment after Week 32 by assessment of the composite endpoint (gastric ulcer or duodenal ulcer-related symptoms or optional esophagogastroduodenoscopy findings) during the prevention therapy.
Time frame: 0 to 52 weeks
Adverse Events During Reflux Esophagitis Maintenance Therapy
Maintenance therapy for healed reflux esophagitis study part: Safety from 8 to 52 weeks for participants who continued the study treatment after Week 32. Number of participants with any adverse event during the period
Time frame: 8 to 52 weeks
Adverse Events During Gastric Ulcer or Duodenal Ulcer Recurrence Prevention Therapy
Prevention of gastric ulcer or duodenal ulcer recurrence associated with long term non-steroidal anti-inflammatory drugs or low-dose aspirin therapy study part: Safety from 0 to 52 weeks for participants who continued the study treatment after Week 32. Number of participants with any adverse event
Time frame: 0 to 52 weeks
First participant enrolled on 24 July 2018 Last participant last visit on 27 December 2022. This study was conducted at a total of 17 sites in Japan.
| Milestone | Group 1 | Group 2 | Group 3 | Group 4 |
|---|---|---|---|---|
| Started | 7 | 21 | 9 | 13 |
| Completed | 6 | 18 | 9 | 12 |
| Not completed | 1 | 3 | 0 | 1 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 |
| Withdrew: Physician decision | 1 | 1 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 |
Maintenance therapy for healed reflux esophagitis study part: Presence/absence of reflux esophagitis relapse from 8 to 32 weeks for all participants by assessment of the composite endpoint (reflux esophagitis -related symptoms or optional esophagogastroduodenoscopy findings) during the maintenance therapy.
| Participants | Group 1 | Group 2 |
|---|---|---|
| Presence of reflux esophagitis relapse | 0 | 1 |
| Absence of reflux esophagitis relapse | 7 | 18 |
Prevention of gastric ulcer or duodenal ulcer recurrence associated with long term non-steroidal anti-inflammatory drugs or low-dose aspirin therapy study part: Presence/absence of gastric ulcer or duodenal ulcer recurrence from 0 to 32 weeks for all participants by assessment of the composite endpoint (gastric ulcer or duodenal ulcer-related symptoms or optional esophagogastroduodenoscopy findings) during the prevention therapy.
| Participants | Group 3 | Group 4 |
|---|---|---|
| Presence of gastric ulcer or duodenal ulcer recurrence | 1 | 0 |
| Absence of gastric ulcer or duodenal ulcer recurrence | 8 | 13 |
Presence/absence of reflux esophagitis relapse from 8 to 52 weeks for participants who continued the study treatment after Week 32 by assessment of the composite endpoint (reflux esophagitis-related symptoms or optional esophagogastroduodenoscopy findings) during the maintenance therapy.
| Participants | Group 1 | Group 2 |
|---|---|---|
| Presence of reflux esophagitis relapse | 1 | 4 |
| Absence of reflux esophagitis relapse | 5 | 12 |
Presence/absence of gastric ulcer or duodenal ulcer recurrence from 0 to 52 weeks for participants who continued the study treatment after Week 32 by assessment of the composite endpoint (gastric ulcer or duodenal ulcer-related symptoms or optional esophagogastroduodenoscopy findings) during the prevention therapy.
| Participants | Group 3 | Group 4 |
|---|---|---|
| Presence of gastric ulcer or duodenal ulcer recurrence | 1 | 0 |
| Absence of gastric ulcer or duodenal ulcer recurrence | 5 | 7 |
Maintenance therapy for healed reflux esophagitis study part: Safety from 8 to 32 weeks for all participants. Number of participants with any adverse event during the period.
| Participants | Group 1 | Group 2 |
|---|---|---|
| Adverse Events During Reflux Esophagitis Maintenance Therapy | 7 | 16 |
Prevention of gastric ulcer or duodenal ulcer recurrence associated with long term non-steroidal anti-inflammatory drugs or low-dose aspirin therapy study part: Safety from 0 to 32 weeks for all participants. Number of participants with any adverse event during the period.
| Participants | Group 3 | Group 4 |
|---|---|---|
| Adverse Events During Gastric Ulcer or Duodenal Ulcer Recurrence Prevention Therapy | 8 | 11 |
Maintenance therapy for healed reflux esophagitis study part: Safety from 8 to 52 weeks for participants who continued the study treatment after Week 32. Number of participants with any adverse event during the period
| Participants | Group 1 | Group 2 |
|---|---|---|
| Adverse Events During Reflux Esophagitis Maintenance Therapy | 6 | 15 |
Prevention of gastric ulcer or duodenal ulcer recurrence associated with long term non-steroidal anti-inflammatory drugs or low-dose aspirin therapy study part: Safety from 0 to 52 weeks for participants who continued the study treatment after Week 32. Number of participants with any adverse event
| Participants | Group 3 | Group 4 |
|---|---|---|
| Adverse Events During Gastric Ulcer or Duodenal Ulcer Recurrence Prevention Therapy | 6 | 6 |
Collected over Serious adverse events were collected from the date of signing of informed consent to 52 weeks or withdrawal. Other adverse events were collected from the start of investigational drug administration to 52 weeks or withdrawal.. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1 | 0/7 (0%) | 0/7 (0%) | 7/7 (100%) |
| Group 2 | 0/21 (0%) | 1/21 (4.8%) | 20/21 (95.2%) |
| Group 3 | 0/9 (0%) | 3/9 (33.3%) | 9/9 (100%) |
| Group 4 | 0/13 (0%) | 2/13 (15.4%) | 11/13 (84.6%) |
| Event | Group 1 | Group 2 | Group 3 | Group 4 |
|---|---|---|---|---|
| Campylobacter gastroenteritisInfections and infestations | 0/7 | 1/21 | 1/9 | 0/13 |
| Chronic recurrent multifocal osteomyelitisMusculoskeletal and connective tissue disorders | 0/7 | 0/21 | 1/9 | 0/13 |
| Pulmonary artery atresiaCongenital, familial and genetic disorders | 0/7 | 0/21 | 1/9 | 0/13 |
| Cyclic vomiting syndromeGastrointestinal disorders | 0/7 | 0/21 | 1/9 | 0/13 |
| Otitis media acuteInfections and infestations | 0/7 | 0/21 | 0/9 | 1/13 |
| Polyarteritis nodosaVascular disorders | 0/7 | 0/21 | 0/9 | 1/13 |
| Skin ulcerSkin and subcutaneous tissue disorders | 0/7 | 0/21 | 0/9 | 1/13 |
| Event | Group 1 | Group 2 | Group 3 | Group 4 |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 6/7 | 6/21 | 2/9 | 4/13 |
| InfluenzaInfections and infestations | 3/7 | 2/21 | 0/9 | 3/13 |
| PharyngitisInfections and infestations | 3/7 | 0/21 | 2/9 | 3/13 |
| GastroenteritisInfections and infestations | 2/7 | 6/21 | 3/9 | 0/13 |
| BronchitisInfections and infestations | 2/7 | 0/21 | 1/9 | 0/13 |
| Thermal burnInjury, poisoning and procedural complications | 2/7 | 0/21 | 0/9 | 0/13 |
| ConstipationGastrointestinal disorders | 1/7 | 5/21 | 1/9 | 0/13 |
| VomitingGastrointestinal disorders | 1/7 | 2/21 | 2/9 | 1/13 |
| PyrexiaGeneral disorders | 1/7 | 1/21 | 2/9 | 0/13 |
| Streptococcal infectionInfections and infestations | 0/7 | 1/21 | 2/9 | 0/13 |
| Age, Continuous(Years) | Group 1 | Group 2 | Group 3 | Group 4 | Total |
|---|---|---|---|---|---|
| Mean | 3.7 ± 1.7 | 10.3 ± 2.2 | 5.2 ± 2.1 | 11.3 ± 2.4 | 8.7 ± 3.7 |
| Age, Customized(Participants) | Group 1 | Group 2 | Group 3 | Group 4 | Total |
|---|---|---|---|---|---|
| <=3 years old | 4 | 0 | 2 | 0 | 6 |
| 4 - 5 years old | 1 | 0 | 3 | 0 | 4 |
| 6 - 7 years old | 2 | 2 | 3 | 1 | 8 |
| 8 - 9 years old | 0 | 8 | 1 | 1 | 10 |
| 10 - 11 years old | 0 | 4 | 0 | 5 | 9 |
| 12 -14 years old | 0 | 7 | 0 | 6 | 13 |
| Sex: Female, Male(Participants) | Group 1 | Group 2 | Group 3 | Group 4 | Total |
|---|---|---|---|---|---|
| Female | 0 | 6 | 5 | 7 | 18 |
| Male | 7 | 15 | 4 | 6 | 32 |
| Race (NIH/OMB)(Participants) | Group 1 | Group 2 | Group 3 | Group 4 | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 7 | 21 | 9 | 13 | 50 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Jul 2018 to primary completion in Dec 2022, 53 months.
Results were first posted in Mar 2026, 3 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: D961H